论文部分内容阅读
由于中年以后的激素改变引起骨量减少,25％以上绝经妇女有骨质疏松的危险。外源性雌激素能有效地防止绝经后骨质丢失,持续治疗可使骨密度得以保持。近年曾两次报道为期2年的,在相似的绝经期妇女人群中进行的双盲、安慰剂对照,不同剂量的经皮17-β雌二醇(E_2)的有效性和耐受性研究,本文报道第3年开放研究的结果,以评价原用药组的耐受性和原安慰剂组的疗效。
More than 25% of menopausal women are at risk of osteoporosis because of hormonal changes that cause bone mass loss after middle age. Exogenous estrogen can effectively prevent bone loss after menopause, continuous treatment can maintain bone mineral density. In recent years there have been two reports of double-blind, placebo-controlled, two-year, double-blind, placebo-controlled studies of the efficacy and tolerability of different doses of transdermal 17-beta estradiol (E_2) This article reports the results of the third year of open study to evaluate the tolerability of the original drug group and the efficacy of the original placebo group.